mechlorethamine has been researched along with Hematologic Diseases in 23 studies
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
Hematologic Diseases: Disorders of the blood and blood forming tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Prospective pharmacokinetic studies to devise a rational dosing strategy for vinblastine in patients receiving ritonavir/lopinavir are warranted." | 1.38 | Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. ( Boro, J; Cheung, MC; Ezzat, HM; Harris, M; Hicks, LK; Leitch, HA; Lima, VD; Montaner, JS, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (86.96) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 2 (8.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| MØLLER, HU | 1 |
| GODTFREDSEN, E | 1 |
| JACOBSON, LO | 2 |
| SPURR, CL | 1 |
| Ezzat, HM | 1 |
| Cheung, MC | 1 |
| Hicks, LK | 1 |
| Boro, J | 1 |
| Montaner, JS | 1 |
| Lima, VD | 1 |
| Harris, M | 1 |
| Leitch, HA | 1 |
| Evens, AM | 1 |
| Hong, F | 1 |
| Gordon, LI | 1 |
| Fisher, RI | 1 |
| Bartlett, NL | 1 |
| Connors, JM | 1 |
| Gascoyne, RD | 1 |
| Wagner, H | 1 |
| Gospodarowicz, M | 1 |
| Cheson, BD | 1 |
| Stiff, PJ | 1 |
| Advani, R | 1 |
| Miller, TP | 1 |
| Hoppe, RT | 1 |
| Kahl, BS | 1 |
| Horning, SJ | 1 |
| KLIMA, R | 2 |
| HORNISCHER, R | 2 |
| TOSZEGI, A | 2 |
| KEYSER, JW | 1 |
| CAPORALETTI, I | 1 |
| GOLL, KH | 1 |
| BRICHTA, G | 1 |
| KUHBOCK, J | 1 |
| REIMER, EE | 1 |
| CONSOLI, G | 2 |
| FOIT, R | 1 |
| SIEBEROVA, R | 1 |
| FLEISCHHACKER, H | 1 |
| KLUG, H | 1 |
| MARKS, EK | 1 |
| Bakemeier, RF | 1 |
| Anderson, JR | 1 |
| Costello, W | 1 |
| Rosner, G | 1 |
| Horton, J | 1 |
| Glick, JH | 1 |
| Hines, JD | 1 |
| Berard, CW | 1 |
| DeVita, VT | 1 |
| Carde, P | 1 |
| Cavalli, F | 1 |
| Diehl, V | 1 |
| Franklin, J | 1 |
| Peiffert, D | 1 |
| Bey, P | 1 |
| Lederlin, P | 1 |
| Conroy, T | 1 |
| Witz, F | 1 |
| Bakchine, H | 1 |
| Brauner, R | 1 |
| Thibaud, E | 1 |
| Rappaport, R | 1 |
| Flamant, F | 1 |
| Griscelli, C | 1 |
| Lemerle, J | 1 |
| Schaison, G | 1 |
| Schweisguth, O | 1 |
| Zucker, JM | 1 |
| Saslaw, S | 1 |
| Carlisle, HN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease[NCT00003389] | Phase 3 | 854 participants (Actual) | Interventional | 1999-06-17 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival is defined as the time from randomization to death or last known alive. The 5-year survival rate is the probability a patient survives 5 years. (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (ABVD) | 0.88 |
| Arm B (Stanford V) | 0.88 |
"Failure-free survival is defined as the time from randomization to the earlier of progression/relapse or death. The 5-year failure-free survival is the probability a patient is failure-free and survives 5 years.~Progression is defined as an increase in size of 25% of the sum of the products of the pretreatment measurements or appearance of new lesions. Significant enlargement of the liver or spleen is evidence of progression. A significant increase in size is defined as > 2.0 cm in distance between costal margin and the inferior margin of either organ.~Relapse is defined as the re-appearance of any clinical evidence of Hodgkin's disease in a patient who has had a complete response. Relapse for partial responders is defined as progressive disease relative to disease status during the partial remission." (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (ABVD) | 0.74 |
| Arm B (Stanford V) | 0.71 |
Number of patients who developed second primary cancers (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years
| Intervention | participants (Number) |
|---|---|
| Arm A (ABVD) | 15 |
| Arm B (Stanford V) | 19 |
2 reviews available for mechlorethamine and Hematologic Diseases
| Article | Year |
|---|---|
Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Clinical Trials, Phase III | 2000 |
[Immediate hematological toxicity during combination chemotherapy-radiotherapy of Hodgkin's disease].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cell Count | 1989 |
2 trials available for mechlorethamine and Hematologic Diseases
| Article | Year |
|---|---|
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dac | 2013 |
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Clinical Trials | 1984 |
19 other studies available for mechlorethamine and Hematologic Diseases
| Article | Year |
|---|---|
About Color Sense Studies.
Topics: Hematologic Diseases; Mechlorethamine | 1948 |
Color perception Studies
Topics: Hematologic Diseases; Mechlorethamine | 1948 |
Radioactive phosphorus (P32) and alkylamines (nitrogen mustards) in the treatment of neoplastic and allied diseases of the hemopoietic system.
Topics: Arylsulfonates; Bone Marrow; Disease; Ethylamines; Hematologic Diseases; Hematopoietic System; Human | 1947 |
Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Bleomy | 2012 |
[Nitrogen mustard therapy of proliferative blood diseases; methods, experiences as well as application possibilities in therapy of carcinoma].
Topics: Hematologic Diseases; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Lymp | 1953 |
[Successful protracted nitrogen mustard therapy in malignant blood disease and cancer].
Topics: Hematologic Diseases; Humans; Mechlorethamine; Neoplasms; Nitrogen Mustard Compounds; Syndrome | 1953 |
[Experiences in nitrogen mustard therapy of the blood diseases].
Topics: Hematologic Diseases; Mechlorethamine; Nitrogen Mustard Compounds | 1952 |
Effect of nitrogen mustard or X-or radium-irradiation treatment on the level of blood serum protein-bound carbohydrate (polysaccharide) in patients with neoplastic diseases.
Topics: Blood; Blood Proteins; Hematologic Diseases; Mechlorethamine; Neoplasms; Nitrogen Mustard Compounds; | 1954 |
[Nitrogen mustards and derivative substances; their use in therapy of blood diseases].
Topics: Hematologic Diseases; Mechlorethamine; Nitrogen Mustard Compounds | 1954 |
[Panmyelophthisis following treatment with tri (beta-chloräthyl) amine hydrochloride (trimitan)].
Topics: Amines; Bone Marrow; Bone Marrow Diseases; Hematologic Diseases; Mechlorethamine; Nitrogen Mustard C | 1954 |
Experiences with nitrogen mustard in the treatment of diseases of the haematological system.
Topics: Hematologic Diseases; Mechlorethamine; Nitrogen Mustard Compounds | 1954 |
[Clinical experiences with rest nitrogen phosphamide esters in hemopathies].
Topics: Biochemical Phenomena; Dimethoate; Esters; Hematologic Diseases; Mechlorethamine; Nitrogen; Nitrogen | 1958 |
[Oxygenated nitrogen mustards in the therapy of malignant blood diseases].
Topics: Cell Respiration; Hematologic Diseases; Mechlorethamine; Nitrogen Mustard Compounds; Respiration | 1954 |
[Use of microdoses of nitrogen mustards].
Topics: Hematologic Diseases; Mechlorethamine; Nitrogen Mustard Compounds | 1952 |
[Oxychlorine in cytostatic therapy of malignant blood diseases].
Topics: Hematologic Diseases; Humans; Mechlorethamine; Nitrogen Mustard Compounds | 1955 |
[Nitrogen mustard therapy for blood diseases and malignant tumors].
Topics: Hematologic Diseases; Hematopoietic System; Mechlorethamine; Neoplasms; Nitrogen Mustard Compounds | 1949 |
The effects of nitrogen mustard on induced erythroblastic hyperplasia in rabbits.
Topics: Animals; Erythroblastosis, Fetal; Erythroblasts; Hematologic Diseases; Hyperplasia; Lagomorpha; Mech | 1949 |
[Chemotherapy and ovarian function. Retrospective analysis in 17 girls treated for malignant tumor or hematologic disease].
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre | 1986 |
Nonhuman primates in evaluation of hematotoxicity.
Topics: Animals; Busulfan; Chlorambucil; Cyclophosphamide; Dactinomycin; Drug-Related Side Effects and Adver | 1969 |